Dr. Polvino, President and Chief Executive Officer (CEO), joined Veloxis in September 2009. Dr. Polvino leads the activities for Veloxis in the US and is responsible for the clinical and regulatory group, including medical affairs, as well as business development activities. Dr. Polvino brings extensive experience in the senior management of pharmaceutical companies together with solid experience in clinical as well as product development.
Earlier in his career, Dr. Polvino was CEO at Helsinn Therapeutics (US), Inc (a private company). In his capacity as the President and CEO of Sapphire Therapeutics, Inc, he successfully sold the company to Helsinn Therapeutics (US) in January 2009.
Dr. Polvino began his career as an MD from UMDNJ-Robert Wood Johnson Medical School, US. He joined the life sciences industry in 1991, upon following training in Internal Medicine at Massachusetts General Hospital and a fellowship in Clinical Pharmacology at the National Institutes of Health, US.
Dr. Polvino had various positions of increasing responsibility within clinical research, drug development, and executive functions at Merck, Wyeth Pharmaceuticals (now Pfizer Inc), and Theravance, Inc, until he joined Sapphire Therapeutics in 2002.
Executive Vice President, Chief Financial Officer
Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.
Prior to joining Veloxis, Mr. Stilou held a number of CFO positions with international technology and Medicare companies.
Mr. Stilou began his career with KPMG in Denmark in 1986. From 1995, he held various senior finance positions within the GN Great Nordic group until 2003.
Mr. Stilou holds a Master of Science in Economics and Business Administration from the Copenhagen Business School.
Dr. Weinberg joined Veloxis in July 2010. He is responsible for managing all Commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification.
Prior to joining Veloxis, Dr. Weinberg was Business Franchise Head at Novartis Pharmaceuticals Corporation in the transplant and infectious disease business unit. In this capacity, he successfully managed and grew the US Transplant business.
Earlier in his career, Dr. Weinberg served as Oncology Business Unit Head at Enzon Pharmaceuticals, Inc, from 2003 to 2005. From 1996 to 2003, Dr. Weinberg held various positions of increasing responsibility within the Global Marketing function at Wyeth Pharmaceuticals, successfully managing brands across multiple therapeutic areas, including oncology, hematology, transplantation, and autoimmune diseases.
Dr. Weinberg received his MD degree from the University of the Witwatersrand School of Medicine, Johannesburg, South Africa, and his MBA degree from INSEAD in Fontainebleau, France.
Senior Vice President, Global Technical Operations
Mr. Bjørn-Christensen joined Veloxis in 2005. He is responsible for CMC (Chemistry, Manufacturing, and Controls), and commercial supply activities. Mr. Bjørn-Christensen has extensive experience in technology transfer, manufacturing and supply chain management.
Earlier in his career, Mr. Bjørn-Christensen served as head of product support at Nycomed A/S, including project management responsibilities for two major technology transfer projects. Before that he served as plant manager for two Nycomed tablet manufacturing plants.
Mr. Bjørn-Christensen holds an MSc in Pharmacy and began his career at Hydro Pharma A/S in Norway working with process optimization and establishment of the center of excellence for pharmaceutical tablet and liquid product manufacture.
Senior Vice President, Global Regulatory Affairs & Quality
Mr. Guido joined Veloxis in 2010. He is responsible for regulatory affairs and quality.
Mr. Guido has extensive experience in the areas of regulatory affairs, quality systems, preclinical screening, clinical research, and product development. These responsibilities have included broad international and domestic regulatory and product development experience encompassing drugs, devices, biologics, and nutritionals.
Earlier in his career, Mr. Guido was senior director and therapeutic area head for cardiovascular medicine within worldwide regulatory strategy for Pfizer, Inc. He has held positions with V.I. Technologies/ Precision Pharma Services, as vice president, quality assurance & regulatory affairs, and positions in regulatory affairs and clinical research at Whitehall-Robins Healthcare, Fresenius Pharma USA, Ayerst Laboratories, Inc., and Mount Sinai Medical Center, New York. Mr. Guido is also a lecturer, at Columbia University.
His undergraduate education is in biology and psychology, and he holds an M.S. in technical communications from the Polytechnic University, New York and an MSc in pharmaceutical medicine from Hibernia College, Dublin.
Senior Vice President, Global Clinical Development & Operations
Ms. Sylvest joined Veloxis in April 2008. She is responsible for clinical development, clinical operations and drug supply.
Ms. Sylvest has extensive experience in conducting global clinical studies both within the pharmaceutical industry and the CRO business. Prior to joining Veloxis, Mrs. Sylvest held the position as director of clinical operations at Rheoscience A/S, where she established the clinical operations department and led the execution and management of the company's clinical studies. She was a member of the management team and involved in establishing the company strategy.
Prior positions for Ms. Sylvest include global project management responsibility at Quintiles A/S and establishment of the NovoSeven® clinical operations surgery group at Novo Nordisk A/S.
Ms. Sylvest holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.